Tango Bypasses IPO Route With SPAC Merger
Cancer Firm Will Raise $353m, List On US Stock Market In Q3
The cancer drug developer was planning to go public later this year, but its series B investor Boxer Capital proposed a merger with its special purpose acquisition corporation, BCTG Acquisition.
You may also be interested in...
BMS Is Latest To Join Synthetic Lethality Bandwagon With Volastra Deal
Deal Snapshot: The drug maker is betting $30m up front and up to $1.1bn in milestone fees for an increasingly popular approach to oncology drug development.
Biotech’s Double-Edged Sword: Extraordinary Funding Run Contributes To Talent Crisis
Finding good leaders always has been hard, but record-breaking VC investment and IPOs, COVID-19 and diversity initiatives have compounded the growing problem.
Deal Watch: Gain To Test Enzyme-Enhancement Tech In Cancer With Zentalis
Argenx partners with Elektrofi and Iontas; China’s Qilu obtains global rights to Peptron’s antibody-drug conjugate and also ends co-development pact with Quantum Genomics.